Inhibition of insulin, glucose-dependant insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity

被引:11
|
作者
Ranganath, LR [1 ]
Beety, JM
Morgan, LM
机构
[1] Epsom Gen Hosp, Dept Chem Pathol, Epsom KT18 7EG, Surrey, England
[2] Univ Surrey, Sch Biol Sci, Guildford GU2 5XH, Surrey, England
关键词
obesity; insulin; GIP; GLP-1; octreotide; heparin; plasma lipoprotein lipase activity;
D O I
10.1055/s-2007-978729
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study examines the immediate effect of modulating postprandial insulin and insulinotropic hormone (glucose-dependent insulinotropic polypeptide, GIP; glucagon-like peptide-1, GLP-1) secretion on the activation of lipoprotein lipase (LPL) in six lean and six obese age-matched women. Subjects were given, on two separate occasions, 340 kcal of carbohydrate alone or combined with an IV infusion of octreotide, (100 mu g infusion from 30 min before the meal for 150 min). Post-heparin LPL activity (10,000 U) was measured on each occasion 120 minutes post-carbohydrate. Following oral carbohydrate postprandial plasma insulin levels were significantly higher in obese subjects than in lean (p<0.01), Glucose tolerance was slightly impaired in obese subjects. Insulin, GIP and GLP-1 secretion post-carbohydrate was markedly reduced by octreotide in lean and obese subjects. LPL activity was similar in the two groups after carbohydrate administration and was unaffected by octreotide. Inhibition of postprandial insulin, GIP and GLP-1 secretion acutely did not reduce post-heparin LPL activity either in lean or obese subjects.
引用
收藏
页码:262 / 266
页数:5
相关论文
共 44 条
  • [41] The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro-GDP): potential mechanistically informed therapeutics in the treatment and prevention of mental disorders
    Mcintyre, Roger S.
    Rasgon, Natalie
    Goldberg, Joseph
    Wong, Sabrina
    Le, Gia Han
    Mansur, Rodrigo B.
    Rosenblat, Joshua D.
    Teopiz, Kayla M.
    Stahl, Stephen M.
    CNS SPECTRUMS, 2025, 30 (01)
  • [42] The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
    Reis-Barbosa, Pedro H.
    Marcondes-de-Castro, Ilitch
    Marinho, Thatiany S.
    Aguila, Marcia Barbosa
    Mandarim-de-Lacerda, Carlos A.
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4613 - 4621
  • [43] Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to-5 studies
    Lingvay, Ildiko
    Cheng, Alice Y. Y.
    Levine, Joshua A.
    Gomez-Valderas, Elisa
    Allen, Sheryl E.
    Ranta, Kari
    Torcello-Gomez, Amelia
    Thieu, Vivian T.
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 965 - 974
  • [44] Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study
    Chu, Lisa
    Bradley, Ryan M.
    Auerbach, Pernille
    Abitbol, Alexander
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4674 - 4683